Quoin Pharmaceuticals Ltd
NASDAQ:QNRX
Intrinsic Value
Quoin Pharmaceuticals Ltd. is a specialty pharmaceutical company engaged in the development of therapeutic products for the treatment of rare and orphan diseases. [ Read More ]
The intrinsic value of one QNRX stock under the Base Case scenario is 3.02 USD. Compared to the current market price of 0.71 USD, Quoin Pharmaceuticals Ltd is Undervalued by 77%.
Valuation Backtest
Quoin Pharmaceuticals Ltd
Run backtest to discover the historical profit from buying and selling QNRX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Quoin Pharmaceuticals Ltd
| Current Assets | 11.3m |
| Cash & Short-Term Investments | 10.7m |
| Other Current Assets | 591k |
| Non-Current Assets | 883.3k |
| Intangibles | 583.3k |
| Other Non-Current Assets | 300k |
| Current Liabilities | 3.6m |
| Accounts Payable | 526.5k |
| Accrued Liabilities | 2.5m |
| Short-Term Debt | 600k |
| Non-Current Liabilities | 2.9m |
| Long-Term Debt | 2.9m |
Earnings Waterfall
Quoin Pharmaceuticals Ltd
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-9.4m
USD
|
|
Operating Income
|
-9.4m
USD
|
|
Other Expenses
|
691.9k
USD
|
|
Net Income
|
-8.7m
USD
|
Free Cash Flow Analysis
Quoin Pharmaceuticals Ltd
QNRX Profitability Score
Profitability Due Diligence
Quoin Pharmaceuticals Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Quoin Pharmaceuticals Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
QNRX Solvency Score
Solvency Due Diligence
Quoin Pharmaceuticals Ltd's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Quoin Pharmaceuticals Ltd's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
QNRX Price Targets Summary
Quoin Pharmaceuticals Ltd
Shareholder Return
QNRX Price
Quoin Pharmaceuticals Ltd
| Average Annual Return | -54.95% |
| Standard Deviation of Annual Returns | 39.86% |
| Max Drawdown | -100% |
| Market Capitalization | 2.6m USD |
| Shares Outstanding | 3 685 970 |
| Percentage of Shares Shorted | 0.42% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Quoin Pharmaceuticals Ltd. is a specialty pharmaceutical company engaged in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Officers
The intrinsic value of one QNRX stock under the Base Case scenario is 3.02 USD.
Compared to the current market price of 0.71 USD, Quoin Pharmaceuticals Ltd is Undervalued by 77%.
You don't have any saved screeners yet
